A RANKL Wrinkle: Denosumab-Induced Hypocalcemia

Journal of Medical Toxicology

Volumn 12, Issue 3, 2016, Pages 305-308

  Laskowski, Larissa K ^a   Goldfarb, David S ^b   Howland, Mary Ann ^a,c   Kavcsak, Kelly ^d   Lugassy, Danny M ^a   Smith, Silas W ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ST JOHN'S UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adverse drug reaction; Cancer; Denosumab; Hypocalcemia; Toxicology

Indexed keywords

ALBUMIN; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CISPLATIN; COLECALCIFEROL; CREATININE; DENOSUMAB; ERGOCALCIFEROL; ETOPOSIDE; GLUCONATE CALCIUM; HEMOGLOBIN; LEUPRORELIN; MAGNESIUM; MAGNESIUM OXIDE; MAGNESIUM SULFATE; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; VITAMIN D; ANTINEOPLASTIC AGENT; BONE DENSITY CONSERVATION AGENT; TNFSF11 PROTEIN, HUMAN; TUMOR PROTEIN;

AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CASE REPORT; ELECTROCARDIOGRAPHY; ERYTHROCYTE TRANSFUSION; FATIGUE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOCALCEMIA; MAGNESIUM BLOOD LEVEL; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; OXYGEN SATURATION; PHOSPHATE BLOOD LEVEL; PROSTATE CANCER; PULSE RATE; SMALL CELL LUNG CANCER; TELEMETRY; WEAKNESS; ANTAGONISTS AND INHIBITORS; BLOOD; BONE TUMOR; CHEMICALLY INDUCED; METABOLISM; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; SECOND CANCER; SECONDARY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DENOSUMAB; HUMANS; HYPOCALCEMIA; MALE; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; PROSTATIC NEOPLASMS; RANK LIGAND; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84961214226     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-016-0543-y     Document Type: Article

References (17)

1. Amgen Inc. Prolia [package insert]. 2015 Mar 2;1–31.
2. Amgen Inc. Xgeva [package insert]. 2014 Dec 5;1–20.
3. Muqeet Adnan M, Bhutta U, Iqbal T, AbdulMujeeb S, Haragsim L, Amer S. Severe hypocalcemia due to denosumab in metastatic prostate cancer. Case Rep Nephrol. 2014;2014:565393.
4. Autio KA, Farooki A, Glezerman IG, Chan A, Schneider CW, Barr HC, et al. Severe hypocalcemia associated with denosumab in metastatic castration-resistant prostate cancer: risk factors and precautions for treating physicians. Clin Genitourin Cancer. 2015;13:e305–9.
5. Qi W-X, Lin F, He A-N, Tang L-N, Shen Z, Yao Y. Incidence and risk of denosumab-related hypocalcemia in cancer patients: a systematic review and pooled analysis of randomized controlled studies. Curr Med Res Opin. 2013;29:1067–73.
6. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012;66:1139–46.
7. Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875–82.
8. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564–71.
9. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TLJ, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361:745–55.
10. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132–9.
11. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–22.
12. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125–32.
13. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379:39–46.
14. Peddi P, Lopez-Olivo MA, Pratt GF, et al. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2013;39:97–104.
15. Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27:1471–9.
16. Sohn W, Simiens MA, Jaeger K, Hutton S, Jang G. The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review. Br J Clin Pharmacol. 2014;78:477–87.
17. Njoh RF, Nguyen A, Sadigh M. Cisplatin induced hypomagnesemic hypocalcemia: a case report and a review of the pathophysiology. J Clin Case Rep. 2013;3:259.